Ribonucleotides are the critical starting materials for the synthesis of mRNA by in vitro transcription.
Minimize risk and complications in the transition from development to industrial production of mRNA therapeutics or vaccines by relying on fit-for-purpose product quality from a high-volume NTP supplier.
- Pandemic-ready supply
Roche has invested in a brand-new manufacturing facility with customized automation technology designed exclusively for mRNA raw material requirements in consistent high quality and scale. - Sustainable and pure products
Choose sustainability without compromise. Our nucleotides are produced through enzymatic catalysis, reducing impurities associated with chemical synthesis and ensuring high purity. - Innovation and expertise
Leverage our extensive experience and expertise based on 30 years of nucleotide manufacturing at one of Europe's largest biotechnology centers in Penzberg, Germany.